Company NewsAesthetic Devices

【South Korea 】LaserOptec pivots to therapeutic lasers, bets on VASCURA 589 for next growth cycle

Jun 17, 2026Local score 8.0

Source image preserved for article context.

Editor's note

This piece relies on CEO Changjin Lee’s statement to Maeil Health as the primary sourcing signal. For buyers, the shift to therapeutic lasers like VASCURA 589 signals a potential supply-chain pivot away from commoditized lifting devices, while the unresolved US litigation and distributor-to-direct sales restructuring in North America pose regulatory and channel risks to watch.

South Korean laser device maker LaserOptec is shifting its growth axis from lifting-focused aesthetic devices toward therapeutic laser systems, betting on its newly commercialized vascular laser VASCURA 589. CEO Changjin Lee told Maeil Health that as the lifting market becomes commoditized, demand for high-barrier therapeutic lasers is rising. The company, which posted a revenue decline to KRW 25.4 billion in 2024 due to US litigation costs and a temporary slowdown in Southeast Asia, expects its North American business to normalize from 2025 onward.

Market signal

Therapeutic laser devices, once considered a niche in the aesthetic market, are regaining attention as the lifting segment overheats. LaserOptec sees this as a structural shift: clinics are returning to core treatment lasers that deliver consistent clinical outcomes. The company's domestic revenue grew over 20% last year and continued rising in the first half of 2025, signaling a recovery in laser demand.

Product pipeline: VASCURA 589 and beyond

LaserOptec's flagship new product is VASCURA 589, a solid-state 589 nm vascular laser using proprietary Raman technology. It targets port-wine stains, hemangiomas, telangiectasia, rosacea, and facial redness, with potential expansion into vascular rejuvenation. The project cost over KRW 4 billion in R&D and involved 10 researchers since 2022. The company expects VASCURA to become its main growth driver over the next 3–5 years. Other key devices include PALLAS, the world's first solid-state UV laser for psoriasis and vitiligo, which eliminates gas replacement costs; and HELIOS 785 Pico, a 785 nm picosecond laser for stubborn pigmentation and multi-color tattoo removal.

Regulatory and channel signals

LaserOptec is restructuring its North American channel from a distributor model to a direct sales network focused on the US West Coast and Texas, and expanding in Canada. US litigation issues are nearing resolution, paving the way for normalized operations by 2026. The company aims to shift its revenue mix from nearly all aesthetic devices to a 70:30 split between aesthetic and therapeutic devices over the long term.

What buyers should watch

For distributors and clinics evaluating laser platforms, LaserOptec's therapeutic lineup offers differentiation in a crowded lifting market. VASCURA 589's solid-state design and high-power yellow wavelength may appeal to clinics seeking precision vascular treatments with lower maintenance costs. The company's direct sales push in North America could mean more competitive pricing and local support for buyers in those regions.

Sourcing context

LaserOptec is a KOSDAQ-listed company (since 2024) and won a $20 million export award in the same year. Its full-line strategy—covering both aesthetic and therapeutic lasers—positions it as a one-stop supplier for clinics. Buyers should note the company's R&D intensity and its focus on high-barrier, proprietary technologies that may offer longer product lifecycles and stronger IP protection.

Source: Read the original report | Published: June 17, 2026